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Pseudoxanthoma Elasticum: the 
End of the Autosomal Dominant 
Segregation Myth
Arthur A.B. Bergen1,2
Pseudoxanthoma elasticum (PXE) is a heritable connective-tissue disorder affecting 
the eye, skin, and vascular system. Recent publications show that PXE exclusively 
segregates in an autosomal recessive fashion. However, the lack of an internation-
ally accepted clinical "gold standard" for PXE, our incomplete knowledge of PXE 
etiology, and the incomplete nature of some molecular, clinical, and environmental 
studies warrant further investigation.
Journal of Investigative Dermatology (2006) 126, 704–705. doi:10.1038/sj.jid.5700129
In this issue, Ringpfeil et al. (2006) nice-
ly illustrate the accumulating evidence 
that pseudoxanthoma elasticum (PXE), 
a rare disorder of the connective tissue 
affecting the eye, skin, and cardiovas-
cular system, is in fact an autosomal 
recessive disease. Putative dominant 
inheritance can be explained by pseu-
dodominance.
Previously, Plomp et al. (2004) 
reviewed the entire PXE literature as 
well as a large PXE family data set from 
The Netherlands and found, since the 
first publication in 1934, descriptions 
of 18 putative dominant PXE families. 
However, upon closer inspection, only 
three of these families had definite PXE 
in two successive generations, which 
could be explained by pseudodomi-
nance. Not a single family with definite 
PXE in three or more generations was 
ever described. The additional 59 fami-
lies from The Netherlands contained 
only three putative autosomal dominant 
PXE families. For two families, domi-
nant inheritance could not be proven. 
The third PXE family, however, with 
an ABCC6 R1459C mutation, remains 
an interesting puzzle and is perhaps 
the always existing “exception to the 
rule” (Plomp et al., 2004). Recently, 
Chassaing et al. (2005) and Miksch et 
al. (2005) addressed the issue of domi-
nant versus recessive PXE in several 
other publications and reached more or 
less the same conclusions as Plomp et 
al. (2004) and Ringpfeil et al. (2006).
So, do we now close the discus-
sion? Do we assume that ten to twenty 
authors from the PXE literature in the 
past have mistakenly described domi-
nant PXE families? Do the latest publi-
cations mark the end of the autosomal 
dominant PXE segregation myth? Yes 
and no.
There is no doubt that PXE segre-
gates in the overwhelming majority 
of families in an autosomal recessive 
fashion. However, at the same time, 
one should be aware of several weak 
points underlying the autosomal reces-
sive conclusion.
First of all, there is no internationally 
accepted definition of minimal clini-
cal diagnostic criteria for the diagno-
sis PXE despite the fact that an attempt 
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was made to define the PXE disease 
phenotype using major and minor cri-
teria (Lebwohl et al., 1994). The lack 
of a minimal "gold standard" that is 
internationally accepted has major 
implications for defining the disease 
state of heterozygote carriers, and thus 
for defining recessive and dominant 
inheritance. This can be illustrated by 
two examples. If Plomp et al. (2004) 
had reviewed the literature using a less 
strict definition of the clinical diagno-
sis PXE, many more putative dominant 
PXE families might have popped up. 
Perhaps some families might even have 
been called dominant. In the current 
paper, Ringpfeil et al. (2006) state that 
“individuals with positive skin biopsy 
and lack of clinical skin manifesta-
tions, but having asymptomatic angioid 
streaks and/or cardiovascular disease, 
were considered minimally affected.” 
Although absolutely correct, these are 
not criteria used in every other study or 
by every other investigator; this makes 
interpretations of Ringpfeil et al.’s data 
difficult. Moreover, their definitions 
get even more complicated in Table 
S1 (“Clinical features of affected indi-
viduals”), where “ophthalmologic find-
ings” are reported not as the presence 
or absence of angioid streaks or other 
more specific fundus features (peau 
d’orange, comet-like streaks, and so on) 
but in the rather vague terms “asymp-
tomatic” and “visual loss.”
Secondly, the recessive/dominant 
discussion is focused on a subset of 
families in which inheritance occurs in 
two successive generations. Little atten-
tion so far has been paid to the 10%–
20% of PXE patients who apparently 
have a single ABCC6 mutation. These 
cases are now easily dismissed in the 
PXE literature with statements such as 
“mutations probably would have been 
missed,” and with suggestions of the 
"involvement of neutral ABCC6 poly-
morphisms,” “other genes,” or “envi-
ronmental factors,” as well as “clinical 
misdiagnosis.” However, these are so 
far unproven hypotheses: no more, no 
less. One striking example is the puta-
tive dominant PXE family described by 
Plomp et al. (2004) with an R1459C 
mutation. Thorough clinical investi-
gation, molecular analysis, and hap-
lotype analysis in this family strongly 
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autosomal dominant PXE 
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suggest a dominant inheritance pat-
tern. Interestingly, in contrast with 
other mutations, the R1459C mutation 
is localized extremely close to the car-
boxy-terminal end of the ABCC6 pro-
tein and leaves all functional sites of 
the protein apparently intact.
Thirdly, if pseudodominance explains 
all cases of putative dominant inheri-
tance in PXE (up to 10%), the carrier 
frequency of PXE must be much high-
er than previously anticipated. This 
conclusion seems to be supported by 
recent findings: calculations on the 
basis of mutation analysis in ABCC6 
suggest a heterozygote frequency for 
PXE of 1.25%–3.0% (Chassaing et al., 
2005). If this theoretical figure is cor-
rect, then the number of (homozy-
gous) PXE patients actually observed 
in populations is unexpectedly low, if 
they are in Hardy–Weinberg equilib-
rium. Chassaing et al. (2005) suggested 
that one explanation could be that a 
number of sequence variations in the 
ABCC6 gene would not lead to PXE at 
all. Indeed, the putative functional role 
of “neutral” ABCC6 polymorphisms, if 
any, has yet to be established. A number 
of so-called neutral variants may con-
tribute to ABCC6 function, dysfunction, 
and pathogenicity, especially in combi-
nation with more “severe” mutations. 
The existence of “mild” and “severe” 
pathogenic variants was also previously 
suggested for the ABCC6 family mem-
ber ABCC7 (Welsh and Smith, 1993) 
and ABCR (Yatsenko et al., 2001). On 
the other hand, this hypothesis was pre-
viously tested and rejected for ABCC6 
in families from The Netherlands, 
because of high intrafamiliar variation 
in the PXE phenotype (Hu et al., 2003).
Fourth, thoroughly investigated 
multigeneration pedigrees in human 
genetics are rare, which may partly 
explain why most PXE families are only 
described in two generations.
Finally, the influence of diet and 
other environmental factors on the PXE 
phenotype in patients and carriers is 
still poorly understood.
In summary, within the limitations 
given above, the current hypothesis is 
that PXE is an autosomal recessive dis-
ease. The recent construction of PXE 
mouse models, in which targeted loss 
of function of abcc6 causes PXE-like 
symptoms, further supports that notion 
(Gorgels et al., 2005; Klement et al., 
2005). These conclusions and findings 
probably mark the end of the autoso-
mal dominant PXE segregation myth.
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Langerhans Cells on Guard in the 
Epidermis: Poised to dSEARCH and . . .?
Mark C. Udey1
Langerhans cells have long been considered to be prototypic immature den-
dritic cells. Results of experiments involving genetically engineered mice pro-
vide surprising new insights into Langerhans cell function in vivo. Nishibu and 
colleagues illustrate how these approaches can be used to visualize Langerhans 
cells in vivo in real time, and to assess aspects of their behavior in unperturbed 
skin and after activation.
Journal of Investigative Dermatology (2006) 126, 705–707. doi:10.1038/sj.jid.5700222
Although immune responses involve 
entire organisms, studies of immunity 
during the past several decades have 
emphasized, and perhaps overempha-
sized, reductionist in vitro experiments. 
Recently, the pendulum has swung back, 
and publication of novel results of in 
vitro experiments in high-profile journals 
essentially requires that authors demon-
strate that their results are physiological-
ly relevant. Although the bar has clearly 
moved up in this regard, the facility with 
which unambiguous in vivo experiments 
can be conducted and interpreted has 
also increased considerably.
The increased ease with which infor-
mative in vivo experiments can be car-
ried out reflects increases in the knowl-
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